BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tsibouris P, Vlachou E, Isaacs PET. Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus. World J Gastrointest Pharmacol Ther 2014; 5(1): 27-39 [PMID: 24605249 DOI: 10.4292/wjgpt.v5.i1.27]
URL: https://www.wjgnet.com/2150-5349/full/v5/i1/27.htm
Number Citing Articles
1
Jusi Wang, Tingyu Chen, Weifeng Tang, Mingqiang Kang, Shuchen Chen. Associations of interleukin-4 and interleukin-4 receptor loci with esophageal squamous cell carcinoma susceptibilityInternational Immunopharmacology 2021; 97: 107659 doi: 10.1016/j.intimp.2021.107659
2
Magnus Halland, David Katzka, Prasad G Iyer. Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagusWorld Journal of Gastroenterology 2015; 21(21): 6479-6490 doi: 10.3748/wjg.v21.i21.6479
3
Frederik Hvid-Jensen, Asbjørn Mohr Drewes. Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?The Lancet 2018; 392(10145): 362 doi: 10.1016/S0140-6736(18)31618-0
4
Omran Alsalahi, Anca D. Dobrian. Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?Frontiers in Oncology 2015; 4 doi: 10.3389/fonc.2014.00373
5
Jennifer L. Schneider, Wei K. Zhao, Douglas A. Corley. Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett’s EsophagusDigestive Diseases and Sciences 2015; 60(2): 436 doi: 10.1007/s10620-014-3349-2
6
Alessandra Pannunzio, Mauro Coluccia. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry LiteraturePharmaceuticals 2018; 11(4): 101 doi: 10.3390/ph11040101
7
ABDULLAH K. ALTWAIRGI. Statins are potential anticancerous agents (Review)Oncology Reports 2015; 33(3): 1019 doi: 10.3892/or.2015.3741
8
Aleksandra M. Urbanska, Selvarangan Ponnazhagan, Masoud Mozafari. Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett EsophagusCancer Research 2018; 78(14): 3747 doi: 10.1158/0008-5472.CAN-18-0206